Australia markets closed

Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
48.55+3.62 (+8.06%)
At close: 04:00PM EST
48.18 -0.37 (-0.76%)
After hours: 07:55PM EST
Full screen
Trade prices are not sourced from all markets
Previous close44.93
Bid0.00 x 900
Ask0.00 x 900
Day's range44.48 - 49.75
52-week range36.91 - 58.10
Avg. volume2,794,691
Market cap124.842B
Beta (5Y monthly)0.42
PE ratio (TTM)18.05
EPS (TTM)2.69
Earnings dateN/A
Forward dividend & yield1.75 (3.89%)
Ex-dividend date26 May 2022
1y target est58.50
  • Motley Fool

    These 3 Stocks Escaped Tuesday's Market Downdraft

    Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.

  • Financial Times

    US judge rules for pharma groups in cancer litigation over Zantac

    A US judge has dismissed thousands of lawsuits claiming that popular heartburn medication Zantac causes cancer, handing a big victory to pharmaceutical companies GSK, Pfizer, Sanofi and Boehringer Ingelheim. US District Judge Robin Rosenberg in West Palm Beach, Florida, said in an order on Tuesday that the almost 2,500 lawsuits filed in federal court by plaintiffs were based on flawed science, and that the only reliable testing of the blockbuster drug undertaken showed an “unprovable risk of cancer”.

  • Motley Fool

    Why Shares of Provention Bio Went Up 30.3% in November

    Shares of Provention Bio (NASDAQ: PRVB) rose 30.3% in November, according to data from S&P Global Intelligence. The pharmaceutical company closed out October at $6.94 and opened November at $7. The move up can be directly tied to the approval of Provention therapy Tzield (teplizumab-mzwv) by the Food and Drug Administration (FDA) on Nov. 17.